Celgene Corporation

Release Summary

CELGENE ANNOUNCES INTERIM TOPLINE DATA FROM TRIAL OF INVESTIGATIONAL ORAL GED-0301 IN PATIENTS WITH ACTIVE CROHN'S DISEASE

Celgene Corporation